Comparison · NCT02765802-sae
Lambda 180 μg vs Lambda 120 μg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lambda 180 μg vs Lambda 120 μg: serious adverse events. Trial comparisons, record NCT02765802-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02765802-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.143 | 0.0401 | 0.399 | wilson | |
| Risk in group 2 | 0.263 | 0.118 | 0.488 | wilson | |
| Risk difference, group 1 minus group 2 | -0.12 | -0.367 | 0.174 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.543 | 0.123 | 2.4 | log | |
| Odds ratio, group 1 over group 2 | 0.467 | 0.0762 | 2.86 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Lambda 180 μg than on Lambda 120 μg | 8.31 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lambda 180 μg | Lambda 180 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.~Peginterferon Lambda-1A | 2 | 14 | EG000 |
| Group 2 | Lambda 120 μg | Lambda 120 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.~Peginterferon Lambda-1A | 5 | 19 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Treatment emergent adverse events were collected on or after the first Lambda injection, through 24 weeks post-treatment, an average of 72 weeks.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
- NCT number
- NCT02765802
- Phases
- PHASE2
- Conditions
- Hepatitis D, Chronic
- Interventions
- Peginterferon Lambda-1A
- Lead sponsor
- EIT Pharma, Inc.
- Results first posted
- 2023-01-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02765802?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02765802-sae